Company Filing History:
Years Active: 2022-2023
Title: Kendall M Mohler: Innovator in Cancer Vaccine Development
Introduction
Kendall M Mohler is a prominent inventor based in San Diego, CA, known for his significant contributions to cancer treatment through innovative vaccine technologies. With a total of 2 patents, Mohler has focused on developing allogeneic whole cell cancer vaccines that aim to enhance the immune response against tumors.
Latest Patents
Mohler's latest patents revolve around tumor cell vaccines. The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. The compositions contain a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to inhibit or reduce expression of one or more immunosuppressive factors by the cells. Additionally, these cells may express or increase expression of one or more immunostimulatory factors and tumor-associated antigens (TAAs), including mutated TAAs. This innovative approach utilizes cancer cell lines that natively express a heterogeneity of tumor-associated antigens and/or neoantigens, providing a comprehensive method for vaccine composition preparation and use.
Career Highlights
Kendall M Mohler is currently associated with Neuvogen, Inc., where he continues to advance his research in cancer immunotherapy. His work has been pivotal in the development of novel therapeutic strategies aimed at improving patient outcomes in cancer treatment.
Collaborations
Mohler collaborates with notable colleagues, including Bernadette Ferraro and Todd Merrill Binder, who contribute to the innovative research environment at Neuvogen, Inc. Their combined expertise fosters a collaborative atmosphere that enhances the development of cutting-edge cancer therapies.
Conclusion
Kendall M Mohler's contributions to cancer vaccine development exemplify the impact of innovative research in the medical field. His work not only advances scientific knowledge but also holds the potential to significantly improve cancer treatment outcomes for patients.